Market Research Logo

Prescription Drugs Market Research Reports & Industry Analysis

In April 2011, the Food and Drug Administration (FDA) announced a new program focused on curbing the abuse and reducing associated risks of prescription opioid painkillers. The Risk Evaluation and Mitigation Strategy (REMS) program focuses primarily on educating doctors about proper pain management, patient selection and improving patient awareness about how to use these drugs safely.

According to the White House, prescription drug abuse has become an epidemic, estimating that in 2007 alone, over 33 million Americans age 12 and older misused opioid painkillers. That same year, drug overdose in the U.S. was one of the leading causes of unintentional injury death, second only to motor vehicle accidents.

One important target of the campaign is the safe disposal of medications. In many cases, doctors have been found to prescribe larger doses of opioids than patients actually use. Many of these pills find their way onto the black market. Additionally, more than half of all non-prescribed painkiller users get their drugs from someone they know. As part of the plan, FDA wants opioid manufacturers to provide prescribing physicians with educational materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

The drugs targeted by the REMS plan include brand name products known under the generic names hydromorphone, oxycodone, morphine, oxymorphone, methadone, transdermal fentanyl, and transdermal buprenorphine.

...Show More ...Show Less


Prescription Drugs Industry Research & Market Reports

  • Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024

    ... projected to register a CAGR of 8.1% during the forecast period.” The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8 billion in 2019, at a CAGR of 8.1%. ... Read More

  • Pediatric Drugs Markets in China

    ... economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic ... Read More

  • Depression Treatment Drugs Industry Forecasts - China Focus

    ... expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in ... Read More

  • Depression Treatment Drugs Companies in China

    ... dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies ... Read More

  • Mental Illness Drugs Markets in China

    ... The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines ... Read More

  • Osteoporosis Drugs Markets in China

    ... economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic ... Read More

  • Hypertension Drugs Markets in China

    ... economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic ... Read More

  • Depression Treatment Drugs Markets in China

    ... The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines ... Read More

  • Blood Disease Drugs Markets in China

    ... The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines ... Read More

  • Europe Pharmaceuticals & Healthcare Q4 2019

    ... to region-specific trends. Themore developed Western markets will continue to be favoured by innovative drugmakers due to stronger regulatory oversight andgreater purchasing power, although growth in these markets will be suppressed by aggressive cost-containment. Revenue ... Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2019

    ... our 2019 new vehicle sales forecasts for Sweden this quarter. We now forecast a 14.2%contraction in the overall market, with the PV segment (-13%) to fall by a smaller amount than the CV segment (-20.7%). Read More

  • Australia Pharmaceuticals & Healthcare Q4 2019

    ... 2019 Key View: Sustainability of government-funded medicines will be increasingly questioned in Australia. A regulatory framework thatmeets the highest international standards is a favourable market attribute. Coalition win should facilitate government support formedium-term healthcare investment. Read More

  • Colombia Pharmaceuticals & Healthcare Q4 2019

    ... issue in Colombia for several years. There is a hope that the pricecaps will allow the government to be more efficient in its medicine spending. Colombia already represents a challengingcommercial environment for foreign pharmaceutical firms. Read More

  • Moldova Pharmaceuticals & Healthcare Q4 2019

    ... income levels reduces the capacity of thepotential consumer market, limiting demand for credit services, investment plans and insurance cover. The country is strugglingwith reconstruction efforts in the aftermath of two cyclones - Idai and Kenneth ... Read More

  • Middle East And North Africa Pharmaceuticals & Healthcare Q4 2019

    ... of the region's electricity mix. Despite ambitious targets in the region, the UAE and Egypt will accountfor 65% of the region's non-hydropower renewables capacity growth. As a result, renewables will play a relatively limited role,accounting ... Read More

  • Asia Pharmaceuticals & Healthcare Q4 2019

    ... environments, it is vital that companies appreciate the varying levels ofinvestment risk and reward that are present in the markets in Asia. Nonetheless, on aggregate, the Asia Pacific region is the mostattractive emerging region globally. Read More

  • Analgesics in Germany

    ... adverse side effects of analgesics if used regularly over a long period of time, as warned by the medical establishment and the media. Another reason for the category decline was weather as Germans used to ... Read More

  • Cough, Cold and Allergy (Hay Fever) Remedies in the US

    ... competition from natural remedies, pharmaceutical-based products are still often preferred by consumers who either are not able to or do not want to skip work to treat their symptoms, or believe that self-medicating with an ... Read More

  • Cough, Cold and Allergy (Hay Fever) Remedies in the US

    ... competition from natural remedies, pharmaceutical-based products are still often preferred by consumers who either are not able to or do not want to skip work to treat their symptoms, or believe that self-medicating with an ... Read More

  • Pharmaceutical Wholesalers (EUROPEAN) - Industry Report

    ... ALLIANCE HEALTHCARE (DISTRIBUTION) LIMITED, CONFRAT EXPLOIT ET REPART PHARMACEUTIQUE and UDG HEALTHCARE PUBLIC LIMITED COMPANY. This report covers activities such as bio-pharmaceuticals, biopharmaceuticals, biologicals, biologics, vaccines and includes a wealth of information on the financial ... Read More

  • Pharmaceutical Manufacturers (SWEDEN) - Industry Report

    ... MCNEIL AB, ABIGO MEDICAL AKTIEBOLAG and PIERRE FABRE PHARMA NORDEN AB. This report covers activities such as bio-pharmaceuticals, biopharmaceuticals, biologicals, biologics, vaccines and includes a wealth of information on the financial trends over the past ... Read More

  • Pharmaceutical Manufacturers (SWEDEN) - Industry Report

    ... including MCNEIL AB, ABIGO MEDICAL AKTIEBOLAG and PIERRE FABRE PHARMA NORDEN AB. This report covers activities such as bio-pharmaceuticals, biopharmaceuticals, biologicals, biologics, vaccines and includes a wealth of information on the financial trends over the ... Read More

  • Pharmaceutical Wholesalers (NORDIC) - Industry Report

    ... including NORSK MEDISINALDEPOT AS, TJELLESEN MAX JENNE A/S and TAMRO OYJ. This report covers activities such as bio-pharmaceuticals, biopharmaceuticals, biologicals, biologics, vaccines and includes a wealth of information on the financial trends over the past ... Read More

  • Pharmaceutical Wholesalers (GLOBAL) - Industry Report

    ... TOHO HOLDINGS CO., LTD., COMPAGNIE D'EXPLOITATION ET DE REPARTITION PHARMACEUTIQUES DE ROUEN and CONFRAT EXPLOIT ET REPART PHARMACEUTIQUE. This report covers activities such as bio-pharmaceuticals, biopharmaceuticals, biologicals, biologics, vaccines and includes a wealth of information ... Read More

  • Pharmaceutical Wholesalers (NORDIC) - Industry Report

    ... NORSK MEDISINALDEPOT AS, TJELLESEN MAX JENNE A/S and TAMRO OYJ. This report covers activities such as bio-pharmaceuticals, biopharmaceuticals, biologicals, biologics, vaccines and includes a wealth of information on the financial trends over the past four ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog